Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erica Rocco

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
JACC. Advances|May 14, 2026
SGLT2 Inhibitors in Cardio-Oncology: A Systematic Review and Meta-AnalysisLuigi Spadafora, Marco Bernardi, Gianmarco Sarto, et al.
Journal of Clinical Medicine|April 26, 2025
Hemoglobin-to-Creatinine Ratio Predicts One-Year Adverse Clinical Outcomes in ST-Elevation Myocardial Infarction: Retrospective and Propensity Score Matched AnalysisLuigi Spadafora, Stefano Cacciatore, Mattia Galli, et al.
The American Journal of Medicine|May 12, 2024
The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-Blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVIDHarlan M Krumholz, Mitsuaki Sawano, Bornali Bhattacharjee, et al.
The Lancet. Infectious Diseases|April 6, 2025
Nirmatrelvir-ritonavir versus placebo-ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trialMitsuaki Sawano, Bornali Bhattacharjee, César Caraballo, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
JACC. Advances|May 14, 2026
SGLT2 Inhibitors in Cardio-Oncology: A Systematic Review and Meta-AnalysisLuigi Spadafora, Marco Bernardi, Gianmarco Sarto, et al.
Journal of Clinical Medicine|April 26, 2025
Hemoglobin-to-Creatinine Ratio Predicts One-Year Adverse Clinical Outcomes in ST-Elevation Myocardial Infarction: Retrospective and Propensity Score Matched AnalysisLuigi Spadafora, Stefano Cacciatore, Mattia Galli, et al.
The American Journal of Medicine|May 12, 2024
The PAX LC Trial: A Decentralized, Phase 2, Randomized, Double-Blind Study of Nirmatrelvir/Ritonavir Compared with Placebo/Ritonavir for Long COVIDHarlan M Krumholz, Mitsuaki Sawano, Bornali Bhattacharjee, et al.
The Lancet. Infectious Diseases|April 6, 2025
Nirmatrelvir-ritonavir versus placebo-ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trialMitsuaki Sawano, Bornali Bhattacharjee, César Caraballo, et al.
Pageof 3